POMME: The New Cohort to Evaluate Long-Term Effects After Prenatal Medicine Exposure
- 106 Downloads
The POMME (PrescriptiOn Médicaments Mères Enfants) cohort has been implemented for the evaluation of the long-term consequences of medicine prenatal exposure. It holds anonymous medical information as well as information on medicine and healthcare reimbursement to the children, from the first day of intra-uterine life until childhood.
This article provides a description of the cohort regarding its structure and content and presents an outlook of the studies that could be performed with this new data source.
Data sources include (1) the French Health Insurance Database (medicines and medical care prescriptions and reimbursements to children and mothers during pregnancy) and (2) the Mother and Child Protection Centre Database (child health certificates at birth, 9 months of age and 24 months of age). Children born in Haute-Garonne (south-west France), over a period of 1 year (from 1 July to 30 June), are registered in POMME every 5 years. The cohort began on 1 July, 2010.
To date, 8372 children have been recorded in POMME. They have reached 7 years of age now. Among them, 4249 (50.8%) are boys, 286 (3.4%) were from multiple pregnancies and 519 (6.2%) were born prematurely. They were prenatally exposed to 9.8 ± 6.1 medications. After birth, drug exposure was greatest in children aged 0–2 years. Children were mostly exposed to paracetamol, anti-infective agents and respiratory system drugs; 908 (10.8%) children presented with at least two signs of psychomotor development disorders.
POMME provides an observatory study on drug exposure and medical care use in children. This innovative cohort would make it possible to assess the risk of the long-term consequences of prenatal medicine exposure.
The authors acknowledge the data providers, who made anonymised data available for their research institution: the French Health Insurance System of Haute-Garonne and the Mother and Child Protection Center of Haute-Garonne. The authors are grateful to the POMME collaborators: Protection Maternelle et Infantile de Haute-Garonne and Caisse Primaire d’assurance Maladie de Haute-Garonne.
Compliance with Ethical Standards
No sources of funding were used to assist in the preparation of this study.
Conflict of interest
Justine Benevent, Caroline Hurault-Delarue, Mélanie Araujo, Jean-Louis Montastruc, Isabelle Lacroix and Christine Damase-Michel have no conflicts of interest that are directly relevant to the content of this study.
This study was performed on anonymised patient data. For this type of study, formal consent is not required.
- 4.Base des médicaments et informations tarifaires. http://www.codage.ext.cnamts.fr/codif/bdm_it/index_presentation.php?p_site=AMELI. Accessed 19 Jul 2018.
- 5.US Food and Drug Administration. Pediatric expertise for advisory panels: guidance for industry and FDA staff. https://www.fda.gov/RegulatoryInformation/Guidances/ucm082185.htm. Accessed 1 Mar 2018.
- 8.Damase-Michel C, Lapeyre-Mestre M, Moly C, Fournié A, Montastruc JL. Drug use during pregnancy: survey in 250 women consulting at a university hospital center [in French]. J Gynecol Obstet Biol Reprod (Paris). 2000;29(1):77–85.Google Scholar
- 12.Martín-Pérez M, López De Andrés A, Barcenilla González MÁ, Jiménez-García R, Hernández-Barrera V, Jiménez-Trujillo I, et al. Parental administration of over-the-counter medication to Spanish children: a population-based national study. J Spec Pediatr Nurs. 2016;21(2):64–73.Google Scholar
- 14.Escourrou B, Bouville B, Bismuth M, Durrieu G, Oustric S. Self-medication in children by parents: a real risk? A cross-sectional descriptive study [in French]. Rev Prat. 2010;60(6 Suppl.):27–34.Google Scholar
- 24.Abbas S, Ihle P, Adler J-B, Engel S, Günster C, Linder R, et al. Psychopharmacological prescriptions in children and adolescents in Germany. Dtsch Arzteblatt Int. 2016;113(22–23):396–403.Google Scholar
- 39.Haute Autorité de Santé. Trouble du spectre de l’autisme: signes d’alerte, repérage, diagnostic et évaluation chez l’enfant et l’adolescent. https://www.has-sante.fr/portail/jcms/c_468812/fr/recommandations-pour-la-pratique-professionnelle-du-diagnostic-de-l-autisme. Accessed 1 Mar 2018.